



Acute myeloid leukemia (AML) is an aggressive hematopoietic 
malignancy, characterized by abnormal proliferation of progenitor 
cells. Age is a fundamental risk factor, with median overall survival 
(OS) <6 months for elderly patients with AML receiving intensive 
therapy [1]. Several measurable and immeasurable factors, including 
poor performance status, adverse cytogenetics, genetic mutations, 
and complications, are responsible for poor prognosis [2-5].
DNA methylation has been demonstrated to silence tumor suppressor 
transcription, contributing to the occurrence of hematopoietic disease 
[6]. Synthesized in the 1960s, the hypomethylating agents (HMAs) 
azacitidine (AZA) and decitabine (DAC) play a role in reactivating 
the silenced genes and inducing the differentiation of leukemia cells 
[7, 8]. Treatment with AZA or DAC in elderly patients with AML was 
investigated in clinical trials. Through the analysis in patients with 
low bone marrow blast count (20%-30%) receiving AZA 75 mg/m2 
or a conventional care regimen (CCR) [best supportive care (BSC), 
low-dose cytarabine, or intensive chemotherapy], an improved OS 
(24.5 versus 16 months) and similar morphologic complete remission 
(CR) (18% versus 16%) were confirmed in the AZA arm [9]. A survival 
advantage was also obtained from the AZA-AML-001 study, designed 
for elderly patients with AML with blasts of > 30% (10.4 versus 
6.5 months) [10]. DAC given at 15 mg/m2/8 h for 3 consecutive 
days showed a relatively higher CR rate (15% versus 0%) but 
nondifferential OS (8 versus 6 months) when compared to BSC [11]. 
Another dosage, which was defined as 20 mg/m2 for 5 days, resulted 
in 17.8% CR, compared to 7.8% with BSC or low-dose cytarabine, 
and a modest 2-month improvement of the median OS (7.7 versus 
5.5 months) [12]. In all mentioned studies, the CR rate ranged from 
15% to 20% using either of the administration schedule. Therefore, 
appropriate combination therapies of HMAs have been initiated. 
In this review, we evaluated the safety and efficacy of combined 
regimens in the treatment of elderly patients with AML.
Combined with chemotherapy
In a previous in vitro experiment, Neil et al. [13] suggested a synergistic 
effect of cytarabine (Ara-C) and AZA in L210 leukemic mice. This 
might be due to deoxycytidine kinase (dCK) inactivity related to Ara-C 
resistance. AZA was shown to induce dCK, phosphorylating Ara-C 
to its active compound Ara-CTP and restoring cell sensitivity toward 
Ara-C [14]. Standard induction chemotherapy in elderly patients with 
AML remains a “3+7” regimen characterized by the combination 
of intermediate-dose Ara-C administered for 7 days with an 
anthracycline for 3 days. Two randomized studies investigated AZA in 
conjunction with DA for treatment of elderly patients with AML in vivo. 
A pilot study aimed at elderly de novo AML patients with a leukocyte 
count of < 20,000/µl revealed a CR rate of 50% and median OS of
8.8 months [15]. However, large sample data from the AML-AZA trial 
failed to demonstrate favorable results, with nonsignificant shorter OS 
in the AZA/DA arm compared to a DA monotherapy arm (15 versus 
21 months), which might be in part explained by imbalances in 
high-risk cytogenetics, lactate dehydrogenase (LDH) levels, and 
unfavorable performance status in the combination arm [16]. Adverse 
events (AEs) were also more common in the combination arm. The 
addition of AZA to DA increased toxicity and did not provide benefits. 
It was noted that the treatment effect was associated with the 
sequence and the time intervals between the doses of each agent. 
Additionally, the optimal schedule was AZA after Ara-C at a time when 
tumor DNA synthesis had maximally recovered [13]. Therefore, an 
optimal administration schedule and further clinical trials need to be 
further surveyed and studied.
Qin et al. [17] designed an in vitro experiment combining Ara-C with 
DAC in human leukemia cell lines HL60, ML-1, RAji, and Jurkat. The 
authors found through measurements of the half-maximal inhibitory
 concentration (IC50) that the combination of DAC and Ara-C showed
an additive or synergistic induction of cell death in all cell lines. In
addition, a sequential schedule with DAC followed by Ara-C was valid.
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Granulocyte colony-stimulating factor (G-CSF) priming induced G0/ 
G1 phase leukemia cells into an S phase, enhancing cell response 
to DAC. Then, DAC (15 mg/m2 D1–5) plus CAG (termed D-CAG, 
comprising Ara-C [10 mg/m2, q12h, D3–9], aclarubicin [10 mg/day, 
D3–6], and G-CSF [300 µg/day, D0–9]) was designed to treat older 
AML patients [18]. Overall response rate (ORR) was achieved by 
70 patients (82.4%), and CR was 64.7% after the first cycle. The 
median OS for all patients was 10 months (1-42 months), with 
a 1-year OS probability of 46.23%. This regimen was well tolerated, 
with induction mortality of only 4.4%. The results verified that the 
D-CAG regimen was superior to DAC monotherapy when compared 
with historical data.
Homoharringtonine (HHT), an alkaloid from Chinese natural plants, 
was considered a potential treatment for leukemia. Geng et al. [19] 
verified the enhanced effect of DAC plus HHT for inhibiting the viability 
of AML-derived Kg-1a cells. In a randomized Chinese study, the CR 
rate was statistically different between three treatment arms (DAC 
alone: 21.7%; HAG alone: 48.1%; and combination therapy: 58.2%) 
[20]. The addition of DAC to HAG did not increase toxicities and 
early mortality. No statistical difference in terms of OS was observed, 
which might be due to various consolidation therapy regimens.
Combined with immunotherapy
DAC was shown to act as a sensitizer to immunotherapy, 
eliciting an antitumor cytotoxic T-lymphocyte (CTL) response 
by inducing cluster of differentiation 80 (CD80) expression [21]. 
The immunocompromised status of AML had an impact on the 
antileukemia activities of DAC-based chemotherapy. Because of this, 
there should be an attempt to combine DAC-based chemotherapy 
with haploidentical lymphocyte infusion (HLI) or human leukocyte 
antigen (HLA)-mismatched stem cell microtransplantation (SC-MST) 
to overcome this limitation. A multicenter phase II trial infusing HLI 
followed by 36 hours after the last dose of D-CAG showed a CR 
of 55.2% and ORR of 86.2% after the first cycle [22]. Superior 
survival time was present, with a median OS of 18.2 months and 
2-year OS and disease-free survival (DFS) rate of 59.6% and 
36.9%, respectively. AEs were limited to < 5% incidence of most 
grade III–IV events, except for febrile neutropenia. Consistent results 
were demonstrated in leukemic mice. Combination therapy of D-CAG 
plus SC-MST produced a better CR rate of 81.8% and ORR rate of 
86.4% after the first cycle [23]. There was no ratio difference between 
the cytogenetic and molecular subgroups. The median OS for 
all patients was 17 months, with a 2-year OS of 34.8%, and 
it was also closely related to the treatment cycles of SC-MCT. This 
regimen was well tolerated, with rare nonhematological toxicities. 
Early mortality (within 1 month) was only 4.3%, and no graft versus 
host disease (GVHD) was observed.
Lenalidomide, an immunomodulatory agent, is capable of regulating 
gene expression and phosphatase activity [24]. The combination 
therapy of sequential AZA and lenalidomide demonstrated 
encouraging clinical activity in previously untreated elderly AML 
patients [25]. In a phase II study, 52 older untreated patients were 
administered with AZA 75 mg/m2 D1–7, followed by escalating doses 
(5 mg, 10 mg, 25 mg, and 50 mg) of lenalidomide D8–28 of each 
cycle every 6 weeks [26]. The ORR was 40%, but the median OS 
was 5 months. Median OS was longer for responders compared 
with nonresponders (17.25 versus 3.75 months). The combination 
therapy led to limited grade ≥ 3 toxicities and an early mortality of 
17%. Another phase II study reported the outcome of a combination 
regimen in poor-risk previously treated elderly AML patients [27]. After 
a median of two treatment cycles (1-11), the response rate was 25%, 
and responders showed a greater survival advantage. Neutropenic 
fever was the most common serious AE.
To summarize, the combination of HMAs with immunotherapy 
enhanced the antileukemic effect over a single regimen, and it was 
considered effective and safe for elderly AML patients, especially 
untreated ones.
Combined with histone deacetylase inhibitors
Histone deacetylase inhibitors (HDACis) have been proven to induce 
leukemia cell differentiation and prevent proliferation via blocking the 
cell cycle at the G1 phase [28]. Current published HDACis include 
valproic acid (VPA), vorinostat, entinostat, and panobinostat.
VPA, a short-chained fatty acid, was demonstrated to promote growth 
inhibition, apoptosis induction, and reactivation of p57KIP2 and 
p21CIP1 in leukemic cell lines HL-60 and MOLT4 when combined with 
DAC [29]. However, in vivo, the combination regimen did not show 
antileukemia activity. A phase 1/2 and a phase 1 study revealed that 
the addition of VPA led to neurotoxicity, whose severity depended on 
the dose [30, 31]. A phase II study compared the efficacy and safety 
of DAC monotherapy with the combination therapy [32]. Among 
62 patients with AML, 58 (93.5%) were aged ≥ 60 years. A statistically 
higher CR rate and an approximate 2-month modest improvement 
of the median OS were observed in the DAC monotherapy arm. The 
incidence of AEs was higher with the combination arm, particularly 
neurotoxicity. This unfavorable outcome may be due to the use 
of a particularly weak HDACi and the administration scheduling. 
VPA, AZA, plus all-trans-retinoic acid (ATRA) were also evaluated as 
induction therapies. The result from a phase 1/2 study was favorable, 
with a response rate of 52% for elderly patients with untreated AML 
[33]. A phase II study enrolling 65 patients with median age of 72 years 
(50-87 years) revealed that the best responses were 14 CR and 
3 PR (26%). Median OS was 12.4 months for the whole cohort and 
18.1 months for the untreated AML/myelodysplastic syndrome (MDS) 
group [34]. The use of HDACi was considered to restore sensitivity 
to ATRA, and AZA could enhance the activity of ATRA, inducing 
hypomethylation and reexpression of the retinoic acid receptor-
beta2 (RAR-b2) gene [35, 36]. It is feasible that the combination 
of HMAs with HDACi sensitizes ATRA-resistant AML to the effects of 
ATRA. Vorinostat, an orally administered synthetic HDACi, has a dual 
ability of inhibiting both histone and protein deacetylase. A phase 
I dose-escalation study determined the maximum administered 
dose (MAD) of DAC and vorinostat at 20 mg/m2 for 5 days and 
400 mg/day for 14 days, respectively. For untreated AML, patients 
receiving concurrent therapy showed a higher response rate (46% 
versus 14%) compared to those with sequential therapy. However, 
more serious AEs were reported in the concurrent arm [37].
Panobinostat, a pan-HDACi, was combined with AZA for AML and 
high-risk MDS patients unfit for intensive chemotherapy [38]. During 
the phase Ib stage, the MTD dose of panobinostat was 30 mg. Then, 
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in the phase II stage, patients with AML receiving panobinostat 30 mg 
showed an ORR of 31% (9/29) and an OS of 8 months after a median 
follow-up of 13 months. Most frequently, grade III–IV AEs contained 
febrile neutropenia (22%), nausea (17%), infection (17%), dyspnea 
(17%), and fatigue (13%).
Entinostat exerted antileukemia activity through the inhibition 
of class I HDAC enzymes. However, in a phase 2 MDS/AML trial, 
entinostat presented negative results. Patients with AML receiving AZA 
alone showed longer median OS (7.1 versus 5.3 months) than those 
receiving combination therapy after a median follow-up of 30 months 
[39].
Taken together, it is suggested that epigenetic therapy of AML using 
HDACi and HMAs warrants further investigation. The result from an 
in vitro study designed by Momparler et al. [40] showed that a triple 
combination of DNA methylation, histone methylation, and histone 
deacetylation induced a remarkable synergistic antineoplastic effect 
against human AML cells, providing a possible better treatment 
platform.
Combined with monoclonal antibodies
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal 
antibody, was shown to be effective in elderly AML patients. The 
reason for the combination of AZA and GO was non-cross-resistant 
mechanisms and AZA strengthening the efficacy of GO through 
the increase of the CD33 expression and the decrease of the 
p-glycoprotein expression on the leukemic blasts. In 2008, results 
showing a CR rate of 70% and median OS of 10 months were verified 
in a pilot trial combining hydroxyurea (HU) 1500 mg, AZA 75/m2, and 
low-dose GO 3 g/m2 [41]. Then, a phase II study applied a consistent 
schedule for elderly patients with untreated AML as induction therapy 
[42]. Those achieving CR then received four cycles of AZA alone as 
one consolidation treatment. Patients in the good- or poor-risk cohorts 
classified by age and Eastern Cooperative Oncology Group (ECOG) 
showed a CR rate of > 30% and similar median OS of 11 months. 
The early mortality rate was 7.2% and 13%, respectively. The results 
demonstrated that this combination therapy was a possible option 
for elderly patients, especially poor-risk patients. Walter et al. [43] 
reported the efficacy and safety of GO, AZA, plus vorinostat for 
elderly patients with relapsed/refractory AML. The results of an 
MAD schedule of GO 3 mg/m2 D4–8, vorinostat 400 mg/day D1–9, 
and AZA 75 mg/m2 D1–7 yielded a CR rate of 23.3%. Responders 
lived longer than those who failed therapy but lived at least 1 month 
(7.48 months versus 3.17 months). The treatment was well tolerated, 
with 1-month mortality rate of 9.3%.
Combined with kinase inhibitors
FLT3 tyrosine kinase inhibitor
AML with internal tandem duplication (ITD) mutations in the FLT3 
kinase gene (FLT3/ITD) frequently predicted poor prognosis. Chang 
et al. [44] verified that a combination therapy of FLT3 inhibitor and 
HMAs confers synergistic antileukemic effects on cell apoptosis, 
differentiation, and growth inhibition, which provides a novel 
therapeutic approach.
Midostaurin (MS), an oral inhibitor, had shown a therapeutic effect 
for wild-type and mutated FLT3 AML [45]. Superior anti-AML activity 
was displayed in cultured and primary FLT3-ITD-expressing AML 
cells administered with sequential treatment with DAC and MS [46]. 
A phase I study testing the efficacy and safety of AZA plus MS verified 
modest clinical activity [47]. Of 14 available patients, three patients 
achieved CR and two patients achieved hematology improvement. 
The median OS was 6 months.
Sorafenib, another FLT3 inhibitor, was applied to FLT-3-mutant AML 
cells MV4-11 in association with a DAC in vitro experiment [48]. The 
treatment significantly improved growth inhibition relative to either 
agent alone. In a phase II study, relapse/refractory or elderly AML 
patients received AZA at a dose of 75 mg/m2 for 7 days and sorafenib 
400 mg twice daily. The modest outcome was a response rate of 46% 
and CR of 27% [49].
Aminopeptidase inhibitor
Tosedostat is an oral aminopeptidase inhibitor showing significant 
antileukemic activity [50]. Mawad et al. [51] performed a clinical trial 
using tosedostat with Ara-C or DAC in elderly patients with untreated 
AML or high-risk MDS. Thirty-four patients were randomized to 
receive tosedostat 120 mg D1-21 or 180 mg D1–35 accompanied 
by either Ara-C 1 g/m2 or DAC 20 mg/m2 D1-5. In the tosedostat/
DAC arm, nine patients (53%) achieved CR/CR with incomplete 
count recovery (CRi). Patients receiving treatment of tosedostat 
120 mg/m2 and DAC showed a median OS of 16.7 months. 
The grade III–IV AEs with incidence rate of > 10% were febrile 
neutropenia, fever, pneumonia, and sepsis. Only one patient died 
within 4 months after starting treatment.
Proteasome inhibitor
Preclinical studies in AML cells showed that bortezomib induced 
miR-29b upregulation, which was associated with a clinical response 
to DAC [52]. Thus, a phase I trial of bortezomib and DAC enrolled 
10 elderly poor-risk AML patients. DAC 20 mg/m2 D1–10 plus 
bortezomib (escalated up to 1.3 mg/m2 on Days 5, 8, 12, and 15) as 
an induction therapy showed a CR/CRi rate of 50% in elderly AML 
patients. Nonetheless, a bortezomib-related neuropathy developed 
after repetitive cycles [53].
Combined with bexarotene
Bexarotene, the retinoid X receptor agonist, has been demonstrated 
to be active in non-M3 AML and to induce myeloid differentiation 
in vivo [54]. A phase I study enrolled 19 elderly or relapsed 
AML patients receiving DAC 20 mg/m2 followed by bexarotene 
100 mg/m2 or 200 mg/m2 or 300 mg/m2 D1–5 as induction therapy. 
Though the combination therapy resulted in a modest outcome (CR: 
5.2%; PR:15.8%), it was well tolerated [55].
Conclusion
HMAs improve the outcome in elderly AML patients but are associated 
with relatively low response rates. It has been shown that HMA 
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combination therapy provides a good treatment platform. Attractive 
outcomes have been obtained using a combination of HMAs with CAG 
chemotherapy, immunomodulatory therapy, monoclonal antibodies, 
and proteasome inhibitors, with other regimens warranting further 
investigation.
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